Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis

Journal Article · Fri Nov 17 04:00:00 EST 2006 · Biochemical and Biophysical Research Communications

DOI:https://doi.org/10.1016/j.bbrc.2006.09.049· OSTI ID:20854569

Rajesh, Mohanraj ^[1]; Mukhopadhyay, Partha ^[1]; Batkai, Sandor ^[1]; Godlewski, Grzegorz ^[1]; Hasko, Gyoergy ^[2]; Liaudet, Lucas ^[3]; Pacher, Pal ^[1]

---

1. Section On Oxidative Stress Tissue Injury, Laboratory of Physiological Studies, NIAAA, National Institutes of Health, 5625 Fishers Lane, MSC-9413, Bethesda, MD 20892-9413 (United States)
2. Department of Surgery, UMDNJ-New Jersey Medical School, Newark, NJ 07103 (United States)
3. Department of Intensive Care Medicine, University Hospital, 1011 Lausanne (Switzerland)

Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme which plays an important role in regulating cell death and cellular responses to DNA repair. Pharmacological inhibitors of PARP are being considered as treatment for cancer both in monotherapy as well as in combination with chemotherapeutic agents and radiation, and were also reported to be protective against untoward effects exerted by certain anticancer drugs. Here we show that pharmacological inhibition of PARP with 3-aminobenzamide or PJ-34 dose-dependently reduces VEGF-induced proliferation, migration, and tube formation of human umbilical vein endothelial cells in vitro. These results suggest that treatment with PARP inhibitors may exert additional benefits in various cancers and retinopathies by decreasing angiogenesis.

• OSTI ID: 20854569
• Journal Information: Biochemical and Biophysical Research Communications, Journal Name: Biochemical and Biophysical Research Communications Journal Issue: 2 Vol. 350; ISSN 0006-291X; ISSN BBRCA9
• Country of Publication: United States
• Language: English

Related Subjects

60 APPLIED LIFE SCIENCES
ADP
ANTINEOPLASTIC DRUGS
APOPTOSIS
CELL PROLIFERATION
DNA REPAIR
ENZYMES
IN VITRO
INHIBITION
NEOPLASMS
RIBOSE
VEINS